NewLink Genetics announces Merck has begun rolling submission of licensure application
NewLink Genetics reported that Merck has begun the submission of a rolling BLA to the FDA for V920 (rVSV∆G-ZEBOV-GP, live attenuated). This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by Merck in July 2016. November 15, 2018